Pneumococcal Infections Clinical Trial
Official title:
An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department; A Multicenter Prospective Randomized Open Trial The IMPROVED Project
Background :
Community-acquired pneumonia (CAP) is a threat in industrialized countries. It represents the
6th cause of death. CAP also frequently associates with other disorders responsible for
admission and death. Among bacteria responsible for CAP, Streptococcus pneumonia is a major
pathogen that is commonly involved and frequently leads to severe infection and admission.
Categories at risk for this pathogen have been determined, and can be proposed
anti-pneumococcal vaccination (APV) that efficiently and safely protects from this
microorganism.
In the context of US health services, monocenter pilot experiences have reported improvement
of pneumococcal prophylaxis implementing vaccination procedure at ED. A study that set in New
Mexico (2003) reported a significant increase in APV (from 18% to 84%) when patients at risk
were proposed vaccination at ED. To obtain these results, medical students were specifically
trained and dedicated to screen and vaccinate against St. pneumoniae. Another single center
trial (Tennessee, 2007) for APV at ED obtained an improvement (from 38.8 to 45.4%) when
physicians were alerted for pneumococcal risk by the software they usually utilized at
bedside. However these experiences remain sparse as additional dedicated resources are
required or patients and attending ED physicians can be reluctant to proceed to vaccination
at ED.
Mobile phone and derived communication modalities are current vectors to deliver information
in several fields including education and medicine. Initially used in developing countries,
short-message services (SMS) have improved behaviour of patients in various medical areas. In
France, the investigators have observed that most patients above 50 years of age admitted
after ED visit are equipped with mobile phone and can receive alerts by SMS.
These observations prompt us to propose a multifaceted procedure to improve APV after ED
visit in at-risk patients, combining structured oral interview, written information and SMS
as reminders.
Purpose : The investigators hypothesized that
- a multifaceted intervention to promote anti-pneumococcal vaccination combining a
structured oral interview, a written information to patient and his/her general
practitioner, and a series of 3 SMS,
- improves anti-pneumococcal vaccination at 6 months,
- in at-risk patients (65+ years) visiting the emergency department. In order to answer
this question, the investigators designed an interventional prospective multicenter
randomized study (cluster).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02201030 -
Immunogenicity and Safety Study of NBP606 in Healthy Infants
|
Phase 3 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Completed |
NCT04031846 -
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
|
Phase 3 | |
| Recruiting |
NCT05920499 -
The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage
|
N/A | |
| Completed |
NCT01215175 -
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
|
Phase 1 | |
| Completed |
NCT02892812 -
A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
|
Phase 1 | |
| Completed |
NCT02116998 -
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
|
Phase 2 | |
| Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
| Completed |
NCT01193582 -
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
|
Phase 4 | |
| Completed |
NCT00744263 -
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
|
Phase 4 | |
| Completed |
NCT00492557 -
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
|
Phase 3 | |
| Completed |
NCT00195611 -
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
|
Phase 4 | |
| Completed |
NCT00205803 -
Study Evaluating Pneumococcal Vaccine in Healthy Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT00137605 -
Early Versus Delayed Pneumococcal Vaccination in HIV
|
Phase 1/Phase 2 | |
| Completed |
NCT02531373 -
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
|
Phase 1/Phase 2 | |
| Completed |
NCT03615482 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
|
Phase 3 | |
| Completed |
NCT03565900 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
|
Phase 3 | |
| Completed |
NCT04989465 -
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
|
Phase 4 | |
| Completed |
NCT02547649 -
Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)
|
Phase 2 | |
| Completed |
NCT02573181 -
Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)
|
Phase 2 |